Clinical trials sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.
6
Recruiting trials
10
Conditions studied
Phase breakdown
Phase 1 1Phase 2 3Phase 3 1Not applicable 1
Conditions studied
Recruiting trials led by Changchun GeneScience Pharmaceutical Co., Ltd.
- A Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain
- A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease
- Assessment of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of GenSci120 in Healthy Adult Participants in China.
- Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer
- Nanocrystalline Megestrol for First-line Treatment of Advanced Gastric or Colorectal Cancer With Cancer-related Fatigue
- Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD
Common questions
How many trials is Changchun GeneScience Pharmaceutical Co., Ltd. recruiting for?
Changchun GeneScience Pharmaceutical Co., Ltd. is the lead sponsor of 6 recruiting trials.
Is this list complete?
No. For the full record, search ClinicalTrials.gov.